All News
Filter News
Found 73,987 articles
-
Halberd Corp. Retains Prestigious Patent Law Firm on Covid-19-Related and Other Disease Technologies
10/27/2020
Halberd Corporation (OTC PINK: HALB ) has retained the services of a prestigious Pittsburgh, PA law firm, Ference & Associates , to handle its intellectual property matters. The initial application focuses on patenting Halberds base Covid-19 antibody as well as an entire new class of antibody conjugate.
-
Department of Defense Awards Ology Bioservices Contract to Manufacture and Test Novel Live Attenuated Tularemia Vaccine Candidate
10/27/2020
Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today that the Department of Defense (DOD), through the Joint Science and Technology Office of the Defense Threat Reduction Agency (DTRA), has awarded the company with a contract to manufacture a novel live attenuated tularemia vaccine. The contract value is $6.3 million. The vaccine candidate ATI-1701
-
Ecolab Third Quarter Reported Diluted Continuing Operations EPS $0.85; Adjusted Diluted Continuing Operations EPS $1.15, -24%; Results Show Significant Improvement From Second Quarter
10/27/2020
Ecolab Third Quarter Reported Diluted Continuing Operations EPS $0.85; Adjusted Diluted Continuing Operations EPS $1.15, -24%; Results Show Significant Improvement From Second Quarter ST. PAUL, Minn.--( BUSINESS WIRE )-- Ecolab Inc. (NYSE: ECL): THIRD QUARTER HIGHLIGHTS : Third quarter results showed significant improvement from the second quarter, while still reflecting the divergent impacts from COVID-19 on the business segments.
-
Viveve Launches New Clinical Advisory Board in Urinary Incontinence
10/27/2020
Preeminent urology and urogynecology experts to help guide and advance the companys pivotal U.S. PURSUIT trial in Stress Urinary Incontinence
-
Dexcom Reports Third Quarter 2020 Financial Results
10/27/2020
DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended September 30, 2020. Third Quarter 2020 Financial Highlights: Revenue grew 26% versus the same quarter of the prior year to $500.9 million U.S. revenue growth of 29% and international revenue growth of 17% GAAP operating income of $94.1 million or 18.8% of revenue, an increase of 470 basis points comp
-
Transcat Reports Record Second Quarter Operating Income of $3.1 Million on Strong Service Gross Margin
10/27/2020
Consolidated gross margin up 260 basis points to 27.6% driven by impressive Service segment gross margin of 32.2% Total revenue of $41.6 million consistent with prior-year period in a challenging market environment; Service segment achieved 46 th consecutive quarter of year-over-year growth Quarterly cash from operations of $8.5 million; debt reduced by $5.8 million
-
UK Medicines and Healthcare products Regulatory Agency Begins Rolling Review of Moderna’s mRNA Vaccine Against COVID-19 (mRNA-1273)
10/27/2020
Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has started the rolling review process of mRNA-1273, the Company’s vaccine candidate against COVID-19.
-
Entos Pharmaceuticals Working with Applied Pharmaceutical Innovation to Enable In-house Development and Manufacturing Capability
10/27/2020
Entos is working with Applied Pharmaceutical Innovation (API) to ensure secure supply of inputs for its vaccine production and the ability to expand its Edmonton facilities. API has been providing Entos with enhanced capacity to support its growing team.
-
VeChain, Renji Hospital and DNV GL Held Strategic Partnership Signing Ceremony To Launch World's First Blockchain Intelligent Tumor Treatment Center
10/27/2020
In partnership with VeChain and DNV GL, Renji Hospital, a top-ranked hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has announced the launch of the world's first blockchain-enabled Intelligent Tumor Treatment Center on October 20, 2020.
-
Pulse Electronics Switches to Rimini Street Support for its SAP Applications
10/27/2020
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Pulse Electronics, a leading components manufacturer for the automotive and telecommunications industries, has switched to Rimini Street support for its SAP ECC 6.0 and Business Objects software.
-
Daewoong Pharmaceutical's Long-Acting Niclosamide Shows High Promise Against Upcoming COVID-19 'Twindemic'
10/27/2020
- Influenza A (IVA) animal model confirmed 75% clinical symptom improvement compared to the control group - Broad antiviral efficacy results against SARS-CoV-2 and IVA were presented at the ISIRV-AVG conference
-
ARCpoint Labs of North San Diego Adds Two Additional Test Types to Enhance its COVID-19 Response for Businesses and Consumers
10/27/2020
ARCpoint Labs North San Diego is augmenting its already comprehensive menu of COVID-19 tests for businesses and consumers with two additional molecular tests: The SalivaDirect™ and Abbott ID Now™ tests.
-
Tech Titans Awards BALANCED Media|Technology its Emerging Company Innovation Award
10/27/2020
BALANCED Media|Technology (BALANCED) today announced the company has won the prestigious 2020 Emerging Company Innovation Award from Tech Titans.
-
Citius Pharmaceuticals Issues October 2020 Letter to Shareholders
10/27/2020
-- Company recently licensed cellular therapy for potential treatment of ARDS associated with COVID-19 -- Mino-Lok, Company's lead product, is progressing through Phase 3 trials and, if approved, is positioned for market entry into an estimated $1.5 billion market -- Phase 2b trial for Halo-Lido hemorrhoid treatment expected to begin Q1 2021
-
Ampio Pharmaceuticals, Inc. to Present at the ROTH Capital Healthcare Event "COVID-19 Therapeutics in Development"
10/27/2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today it will present at the ROTH Capital Healthcare Event, "COVID-19 Therapeutics in Development" taking place on Wednesday, October 28, 2020 – 9:00 AM (ET) / 6:00 AM (PT).
-
Exact Sciences Announces Third Quarter 2020 Results
10/27/2020
Exact Sciences Corp. announced that the company generated revenue of $408.4 million for the third quarter ended September 30, 2020, compared to $218.8 million for the same period of 2019.
-
Baxter Supports New Study Showing Blood Purification With Oxiris Filter Set Can Play a Role in the Management of Severely Ill COVID-19 Patients
10/27/2020
Marks largest study of its kind on COVID-19 patients treated with extracorporeal blood purification (EBP) using Oxiris Study investigators assessed serum IL-6 levels, indicators of organ dysfunction and intensive care unit (ICU) mortality rate in patients undergoing EBP with Oxiris Findings provide clinicians with new insights on EBP initiation in COVID-19 patients
-
Appili Therapeutics Announces Additional Funding for Its ATI-1701 Biodefense Program
10/27/2020
Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the Company or Appili), a biopharmaceutical company developing anti-infective drug candidates, today announced updates for the continued development of its ATI-1701 biodefense vaccine program.
-
REGENXBIO to Receive $80.0 Million Milestone Payment from Novartis AG
10/27/2020
Zolgensma is the first gene therapy based on REGENXBIO's NAV® Technology Platform approved by the FDA and other regulatory authorities
-
RetinalGeniX™ Technologies Announces RetinalCam™ a Home Monitoring & Physician Alert System
10/27/2020
RetinalGeniX™ Technologies, Inc. www.retinalgenix.com announced today the launch of its RetinalCam™ Home Monitoring & Physician Alert System